AXSMAxsome Therapeutics, Inc.
$168.44+45% 1Y
$168.44
$116.0152 weeks$255.17
The financials
Axsome Therapeutics, Inc. by the numbers
Axsome Therapeutics, Inc. (AXSM) reported revenue of $218M in Q2 2026 (quarter ended Jun 30, 2026), up 46% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $51M. For the full year FY2025, revenue was $638M (+66% year on year) and net income −$183M. Its largest product in Q2 2026 was Royalty And Milestone at $2.0M, 66% of the disclosed total, well ahead of Milestone at 18%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $218M | $150M | +46% |
| Gross profit | $205M | $137M | +50% |
| Operating income | −$50M | −$37M | n/a |
| Net income | −$51M | −$48M | n/a |
| Diluted EPS | −$0.99 | −$0.97 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Royalty And Milestone | $2.0M | 66% |
| Milestone | $546K | 18% |
| Royalty | $500K | 16% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $3.1M (+9.4%)
Royalty And Milestone grew +87% year on yearRoyalty -54% year on year
Segment Latestquarter on quarteryear on year
- Royalty And Milestone$2.0M$2.0Mquarter on quarter +12%year on year +87%+12%+87%
- Milestone$546.0K$546.0Kquarter on quarter +9.2%year on year n/a+9.2%n/a
- Royalty$500.0K$500.0Kquarter on quarter 0.00%year on year -54%0.00%-54%